Neuropsychological Symptoms of Juvenile-Onset Batten Disease: Experiences From 2 Studies

Abstract

Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a progressive and fatal autosomal-recessive inherited lysosomal storage disorder of childhood. Core symptoms include vision loss, seizures, and mental and motor decline. This article presents data from 2 studies of neuropsychological function in juvenile neuronal ceroid lipofuscinosis. In the first cross-sectional pilot study, 15 children with genetic or clinicopathologic confirmation of juvenile neuronal ceroid lipofuscinosis completed a brief test of attention (mean age = 14.3 ± 2.9 years, range = 8.75-18.74 years; 7 males, 8 females). Average attention performances were significantly below age-expected normative data. A second longitudinal study was then initiated to study neuropsychological function in greater depth, including change in function over time. The authors have enrolled 18 children to date (mean age = 12.88 ± 3.59 years, range = 6.26-18.65; 11 males, 7 females). Of these, 5 children have completed a second (annual) re-evaluation. Results thus far indicate significant impairment in domains of auditory attention, memory, estimated verbal intellectual function, and verbal fluency. Neuropsychological impairment was significantly correlated with disease duration and with motor function as assessed by a disease-specific clinical neurologic rating scale. There was no significant difference between males and females in neuropsychological test performance. Neuropsychological function was worse among children with a positive seizure history. Juvenile neuronal ceroid lipofuscinosis—affected children exhibited significant and pervasive impairments on tests of auditory attention, verbal memory and repetition, verbal fluency, and an estimate of verbal intellectual ability. Preliminary follow-up data from an annual reassessment showed progressive declines in cognitive function, in particular on a task of working memory. Neuropsychological deficits are pervasive and progressive. Future research will focus on clarifying the relationship among disease duration, motor function, and neuropsychological performances, including the relative sensitivity of neuropsychological testing at different stages of motor impairment or disease duration.

Keywords

Batten disease neuronal ceroid lipofuscinoses neuropsychological assessment

Get full access to this article

View all access options for this article.

References

Santavuori P. , Lauronen L. , Kirveskari E. , Åberg L. , Sainio K. , Autti T. Neuronal ceroid lipofuscinoses in childhood . Neurol Sci. 2000;21:S35-S41.

Rider JA , Rider DL Thirty years of Batten disease research: present status and future goals. Mol Genet Metab. 1999;66: 231-233.

Boustany R-M. Batten disease or neuronal ceroid lipofuscinosis . In: Moser HW , ed. Handbook of Clinical Neurology. Vol 22(66). Maclean, Va: Elsevier Science B.V.; 1996:671-700.

Phillips SN , Benedict JW , Weimer JM , Pearce DA CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res. 2005;79:573-583.

Munroe PB , Mitchison HM , O'Rawe AM , et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet. 1997;61:310-316.

Lou HC , Kristensen K. A clinical and psychological investigation into juvenile amaurotic idiocy in Denmark. Dev Med Child Neurol. 1973;15:313-323.

Lamminranta S. , Åberg LE , Autti T. , et al. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45:8-17.

Åberg L. , Kirveskari E. , Santavuori P. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia. 1999;40: 796-799.

Marshall FJ , de Blieck EA , Mink JW , et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology. 2005;65:275-279.

10.

Reynolds CR , Bigler ED Test of Memory and Learning. Examiner's Manual. Austin, Tex: Pro-Ed; 1994.

11.

Psychological Corporation. Wechsler Intelligence Scale for Children—Fourth Edition. Manual. San Antonio, Tex: The Psychological Corporation; 2003.

12.

Psychological Corporation. WAIS-III, WMS-III. Technical Manual. San Antonio, Tex: The Psychological Corporation; 2002.

13.

Sheslow D. , Adams W. WRAML: Wide Range Assessment of Memory and Learning. Administration Manual . Wilmington, Del: Wide Range; 1990.

14.

Wechsler D. Wechsler Memory Scale—Third Edition. San Antonio, Tex: The Psychological Corporation; 1997.

15.

Semel E. , Wiig EH , Secord WA Clinical Evaluation of Language Fundamentals—Third Edition. Technical Manual. San Antonio, Tex: The Psychological Corporation; 1995.

16.

Korkman M. , Kirk U. , Kemp S. NEPSY: A Developmental Neuropsychological Assessment. Subtest Administration . San Antonio, Tex: The Psychological Corporation; 1998.

17.

Rothberg PG , Ramirez-Montealegre D. , Frazier SD , Pearce DA Homogeneous polymerase chain reaction nucleobase quenching assay to detect the 1-kbp deletion in CLN3 that causes Batten disease. J Mol Diagn. 2004;6:260-263.

18.

Bäckman ML , Santavuori PR , Åberg LE , Aronen ET Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005 ; 49:25-32.

19.

Adams H. , de Blieck EA , Mink JW , et al. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48:259-264.

20.

Kristensen K. , Lou HC Central nervous system dysfunction as an early sign of neuronal ceroid lipofuscinosis (Batten's disease). Dev Med Child Neurol. 1983;25:588-590.

21.

Krivit W. , Aubourg P. , Shapiro E. , Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol. 1999;6:377-382.

22.

Peters C. , Balthazor M. , Shapiro EG , et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996 ;87:4894-4902.

23.

Krivit W. , Peters C. , Shapiro E. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 1999;12:167-176.

24.

Shapiro E. , Lockman LA , Balthazor M. , Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis. 1995;19:413-429.